The plasma concentration of granulocyte elastase in complex with a, proteinase inhibitor was determined in 32 patients with rheumatoid arthritis and eight with seronegative spondarthritis complicated by peripheral joint synovitis. Most patients had concentrations of complex which were within the range of the control group when measured by an 'in-house' enzyme linked immunosorbent assay, though several of the patients with rheumatoid arthritis had raised concentrations. 
was determined in 32 patients with rheumatoid arthritis and eight with seronegative spondarthritis complicated by peripheral joint synovitis. Most patients had concentrations of complex which were within the range of the control group when measured by an 'in-house' enzyme linked immunosorbent assay, though several of the patients with rheumatoid arthritis had raised concentrations. When the complexes were measured by a commercially available assay, however, much higher values were obtained for many of the patients with rheumatoid arthritis. Evidence is presented indicating that the commercially available assay may suffer seriously from interference by rheumatoid factor. The possibility is discussed that most patients with rheumatoid arthritis may have plasma concentrations of elastase-acPI which are normal or only slightly raised, and that previously published reports using assay systems similar to that available commercially might also have produced falsely raised values for many individuals with rheumatoid arthritis.
Elastase-alPI has been measured in plasma or synovial fluid samples from patients with rheumatoid arthritis as an indication of polymorphonuclear activation and elastase release4 5 15 (BDH, Dorset), according to the instructions provided. This assay uses plastic tubes coated with antibodies to polymorphonuclear elastase. The complex present in the sample binds to these antibodies through its elastase component and is detected with an alkaline phosphatase labelled antibody directed at the ajPI component.
In-house elastase-a,PI assay The samples were also assayed in triplicate by an ELISA developed in house as follows. Nunc Immunoplate I microwell plates (Gibco BRL, Paisley) were coated overnight at 4°C with sheep antihuman elastase (Serotec, Oxford) in phosphate buffered saline pH 7-2. Plasma samples were prediluted 50 times with dilution/wash buffer (phosphate buffered saline containing 0-5 M NaCl, 0 1% Tween 20, pH 7-2) and incubated in the coated microwells at room temperature. After two hours the plates were washed three times with dilution/wash buffer, incubated with rabbit antihuman al antitrypsin (Dako, Bucks) for one hour at room temperature, and washed a further three times. Horseradish peroxidase labelled swine antirabbit immunoglobulin (affinity purified; Dako, Bucks) was then added to each well and the plates incubated for a further hour at room temperature. After a further three washes substrate solution (0-1 M citric acid-phosphate buffer, pH 5 0, containing 8 mg o-phenylenediamine and 5 Id of 30% H202 per 12 ml of buffer) was added to each well and the plate incubated for 15 minutes in the dark. The reaction was stopped by the addition of 1 (343 3 [tg/l). With the commercial assay method a similar peak was obtained but, in addition, a larger peak was found in fractions 5-8 with a maximum of 143-3 [ig/l in fraction 6. This peak represented a recovery of aproximately 32% of the 911-1 -Ig/l difference found between the two assay methods for the initial sample and coincided with a peak in rheumatoid factor levels. Significantly, the recovery of rheumatoid factor in this peak was incomplete with approximately 75% of the rheumatoid factor in the original injected sample being recovered. In addition, aggregation of the fractions containing rheumatoid factor occurred during storage before complex concentrations were determined. This would probably result in substantially less rheumatoid factor than indicated being present in the fractions at the time the concentrations of elastase-a,PI were determined, and hence less interference with the assay than expected.
Discussion
The most likely explanation for the discrepancy between the two assay methods is the interference by rheumatoid factor in the commercially available Merck PMN elastase assay. Although it is possible that some factor other than rheumatoid factor is the interfering substance, this is unlikely as it must meet the criteria of The small number and lack of controls matched for age and sex in this preliminary study are not likely to account for the difference as our normal range is similar to those reported previously and, also, a lack of dependency of elastase-ct,PI concentrations on age and sex has been reported.'2 Similarly, the patients in this study reflected a range of disease activity and duration as in previous studies.
Whether or not plasma elastase-ut1Pl will be of prognostic use must now be further evaluated in the light of these findings and a large longitudinal study is currently in progress to consider this problem. The effects of drug treatment on elastase-u 1Pl concentrations will also be examined, though previous reports have indicated a decrease in concentrations with antirheumatic treatment. 5 12 Depending upon the assay method used, however, such a decrease in elastase-u ,PI concentrations may actually be due partly or totally to a decrease in rheumatoid factor levels, which has been reported to occur with some types of antirheumatic treatment. 20 21 This work was supported by a grant from the Arthritis and Rheumatism Council for Research. We would like to thank Jean Higginson and Joane Gossage for the measurement of rheumatoid factor levels and Professor G Gowland for helpful discussion.
One of the Merck PMN elastase assay kits used in this studv was a kind gift of BDH (Dorset). 
